F-star Therapeutics (F-star Therapeutics) Gross Profit : $21.18 Mil (TTM As of Sep. 2022)

View and export this data going back to 2020. Start your Free Trial

What is F-star Therapeutics Gross Profit?

F-star Therapeutics's gross profit for the three months ended in Sep. 2022 was $1.13 Mil. F-star Therapeutics's gross profit for the trailing twelve months (TTM) ended in Sep. 2022 was $21.18 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. F-star Therapeutics's gross profit for the three months ended in Sep. 2022 was $1.13 Mil. F-star Therapeutics's Revenue for the three months ended in Sep. 2022 was $1.13 Mil. Therefore, F-star Therapeutics's Gross Margin % for the quarter that ended in Sep. 2022 was N/A%.

F-star Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2022 => No sustainable competitive advantage

F-star Therapeutics Gross Profit Historical Data

The historical data trend for F-star Therapeutics's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

F-star Therapeutics Gross Profit Chart

F-star Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Gross Profit

28.32

11.26

21.17

F-star Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Gross Profit	Get a 7-Day Free Trial							0.75	17.50	2.55	-	1.13

Competitive Comparison of F-star Therapeutics's Gross Profit

For the Biotechnology subindustry, F-star Therapeutics's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

F-star Therapeutics's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, F-star Therapeutics's Gross Profit distribution charts can be found below:

* The bar in red indicates where F-star Therapeutics's Gross Profit falls into.

F-star Therapeutics Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

F-star Therapeutics's Gross Profit for the fiscal year that ended in Dec. 2021 is calculated as

Gross Profit (A: Dec. 2021 )	=	Revenue	-	Cost of Goods Sold
	=	21.167	-	0
	=	21.17

F-star Therapeutics's Gross Profit for the quarter that ended in Sep. 2022 is calculated as

Gross Profit (Q: Sep. 2022 )	=	Revenue	-	Cost of Goods Sold
	=	1.125	-	0
	=	1.13

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $21.18 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

F-star Therapeutics's Gross Margin % for the quarter that ended in Sep. 2022 is calculated as

Gross Margin % (Q: Sep. 2022 )	=	Gross Profit (Q: Sep. 2022 )	/	Revenue (Q: Sep. 2022 )
	=	(Revenue - Cost of Goods Sold)	/	Revenue
	=	1.13	/	1.125
	=	N/A %

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.

F-star Therapeutics (NAS:FSTX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

F-star Therapeutics had a gross margin of N/A% for the quarter that ended in Sep. 2022 => No sustainable competitive advantage

F-star Therapeutics Gross Profit Related Terms

Thank you for viewing the detailed overview of F-star Therapeutics's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.

F-star Therapeutics (F-star Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » F-star Therapeutics Inc (NAS:FSTX) » Definitions » Gross Profit

Comparable Companies

Traded in Other Exchanges

N/A

Address

Babraham Research Campus, Eddeva B920, Cambridge, GBR, CB22 3AT

Website

https://www.f-star.com

F-star Therapeutics Inc is a clinical-stage biopharmaceutical company developing tetravalent bispecific antibodies for a paradigm-shift in cancer therapy. By developing medicines that seek to block tumor immune evasion, the company's goal is to offer patients greater and more durable benefits than immuno-oncology treatments.

Executives

Geoffrey Race	director	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Edward Jr Benz	director	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Darlene M Deptula-hicks	officer: See Remarks	C/O ICAD, INC., 98 SPIT BROOK ROAD, SUITE 100, NASHUA NH 03062
Eliot Forster	director, officer: PRESIDENT AND CEO	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Nessan Bermingham	director	890 WINTER STREET, WALTHAM MA 02451
Louis Kayitalire	officer: CHIEF MEDICAL OFFICER	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Neil Brewis	officer: CHIEF SCIENTIFIC OFFICER	C/O EDDEVA B920, BABRAHAM RESEARCH CAMPUS, CAMBRIDGE X0 CB22 3AT
Pamela M. Klein	director	35 PARKWOOD DRIVE, SUITE 210, HOPKINTON MA 01748
Krol Patrick Johan Hendrik	director	GUSTAV MAHLERPLEIN 3, AMSTERDAM P7 1082 MS
Garrett Winslow	officer: General Counsel and Secretary	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Lori Firmani	officer: VP of Finance and Treasurer	35 PARKWOOD DRIVE, C/O SPRING BANK PHARMACEUTCALS, INC., HOPKINTON MA 01748
Scott Andrew Smith	director	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Timothy P Clackson	director	C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Christiana Bardon	director, 10 percent owner	86 SOUTH STREET, C/O SPRING BANK PHARMACEUTICALS, INC., HOPKINTON MA 01748
Mpm Oncology Impact Management Lp	10 percent owner	399 BOYLSTON STREET, SUITE 1100, BOSTON MA 02116